{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:04:37Z","timestamp":1768687477033,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T00:00:00Z","timestamp":1318377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10147-011-0328-x","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T01:43:35Z","timestamp":1318297415000},"page":"584-589","source":"Crossref","is-referenced-by-count":29,"title":["Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan"],"prefix":"10.1007","volume":"17","author":[{"given":"Chikashi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shiseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousei","family":"Matsuei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,12]]},"reference":[{"key":"328_CR1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV (2003) Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N Engl J Med 349:1451\u20131464","journal-title":"N Engl J Med"},{"key":"328_CR2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"328_CR3","doi-asserted-by":"crossref","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F et al (2009) International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH annual meeting abstracts 114:1126","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"328_CR4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432","journal-title":"N Engl J Med"},{"key":"328_CR5","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758\u20133765","journal-title":"Blood"},{"key":"328_CR6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.1998.00823.x","volume":"102","author":"E Mensink","year":"1998","unstructured":"Mensink E, van de Locht A, Schattenberg A et al (1998) Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102:768\u2013774","journal-title":"Br J Haematol"},{"key":"328_CR7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","volume":"107","author":"S Branford","year":"1999","unstructured":"Branford S, Hughes TP, Rudzki Z (1999) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107:587\u2013599","journal-title":"Br J Haematol"},{"key":"328_CR8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","volume":"9","author":"T Zhang","year":"2007","unstructured":"Zhang T, Grenier S, Nwachukwu B et al (2007) Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 9:421\u2013430","journal-title":"J Mol Diagn"},{"key":"328_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"328_CR10","doi-asserted-by":"crossref","unstructured":"Paschka P, Branford S, Lorentz C et al (2004) Comparison of \u201clog reduction from median pretherapeutic value\u201d vs ratio BCR-ABL\/ABL to express the therapeutic response in CML patients. ASH annual meeting abstracts 104:1013","DOI":"10.1182\/blood.V104.11.1013.1013"},{"key":"328_CR11","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112:3330\u20133338","journal-title":"Blood"},{"key":"328_CR12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.leukres.2006.07.021","volume":"31","author":"J Rulcova","year":"2007","unstructured":"Rulcova J, Zmekova V, Zemanova Z et al (2007) The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 31:483\u2013491","journal-title":"Leuk Res"},{"key":"328_CR13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307\u2013310","journal-title":"Lancet"},{"key":"328_CR14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.leu.2402392","volume":"16","author":"SE Langabeer","year":"2002","unstructured":"Langabeer SE, Gale RE, Harvey RC et al (2002) Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 16:393\u2013399","journal-title":"Leukemia"},{"key":"328_CR15","first-page":"481","volume":"50","author":"F Yagasaki","year":"2009","unstructured":"Yagasaki F, Niwa T, Abe A et al (2009) Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki 50:481\u2013487","journal-title":"Rinsho Ketsueki"},{"key":"328_CR16","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444","journal-title":"Blood"},{"key":"328_CR17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"328_CR18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.leukres.2007.03.031","volume":"32","author":"NC Cross","year":"2008","unstructured":"Cross NC, Hughes TP, Hochhaus A et al (2008) International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 32:505\u2013506","journal-title":"Leuk Res"},{"key":"328_CR19","doi-asserted-by":"crossref","unstructured":"M\u00fcller MC, Munjal U, Erben P et al Stability of conversion factors for BCR-ABL monitoring\u2014implications for the frequency of validation rounds. ASH annual meeting abstracts 116:893","DOI":"10.1182\/blood.V116.21.893.893"},{"key":"328_CR20","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P et al (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116:e111\u2013e117","journal-title":"Blood"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0328-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-011-0328-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0328-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:53:27Z","timestamp":1639094007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-011-0328-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s10147-011-0328-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,12]]}}}